EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Jay L Patel, Alessandro Rambaldi, William E Shomali, Stephen T Oh, Kensuke Usuki, Claire N Harrison, Ellen K Ritchie, Luke P Akard, Juan Carlos Hernández-Boluda und 9 weitere

NEJM Evidence · 26.08.2025 · 4 (9)

DOI: 10.1056/evidoa2500017 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift NEJM Evidence, erschienen am 26.08.2025. Verfasst von Srdan Verstovsek und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 1, Pyrimidines, Pyrroles, Morpholines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 1PyrimidinesPyrrolesMorpholinesAntineoplastic AgentsHumansMaleMiddle AgedFemaleAdultAgedGene RearrangementAged, 80 and overYoung AdultTreatment Outcome

Substanzen

Receptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanpemigatinibPyrimidinesPyrrolesMorpholinesAntineoplastic Agents

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston.
  • Saint-Louis Hospital, Greater Paris University Hospitals, Paris Cité University, Paris.
  • Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Careggi University Hospital, University of Florence, Florence, Italy.
  • ARUP Laboratories, Huntsman Cancer Institute, and University of Utah School of Medicine, Salt Lake City.
  • Department of Oncology and Hematology, University of Milan, Milano, Italy.
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Zitieren

APA

Verstovsek, S., Kiladjian, J. J., Vannucchi, A. M., Patel, J. L., Rambaldi, A., Shomali, W. E., Oh, S. T., Usuki, K., Harrison, C. N., Ritchie, E. K., Akard, L. P., Hernández-Boluda, J. C., Huguet, F., Colucci, P., Zhen, H., Oliveira, N., Gilmartin, A., Langford, C., George, T. I., …, & Gotlib, J. (2025). Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement. NEJM Evidence, 4(9). https://doi.org/10.1056/evidoa2500017

Vancouver

Verstovsek S, Kiladjian JJ, Vannucchi AM, Patel JL, Rambaldi A, Shomali WE, et al. Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement. NEJM Evidence. 2025;4(9). doi:10.1056/evidoa2500017

BibTeX
@article{Verstovsek2025,
  author = {Verstovsek, Srdan and Kiladjian, Jean-Jacques and Vannucchi, Alessandro M and Patel, Jay L and Rambaldi, Alessandro and Shomali, William E and Oh, Stephen T and Usuki, Kensuke and Harrison, Claire N and Ritchie, Ellen K and Akard, Luke P and Hernández-Boluda, Juan Carlos and Huguet, Françoise and Colucci, Philomena and Zhen, Huiling and Oliveira, Natalia and Gilmartin, Aidan and Langford, Cheryl and George, Tracy I and Reiter, Andreas and Gotlib, Jason},
  title = {Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement},
  journal = {NEJM Evidence},
  year = {2025},
  volume = {4},
  number = {9},
  doi = {10.1056/evidoa2500017}
}
Kostenlos starten →